Abbott India Limited, a leading name in the Indian pharmaceutical sector, has announced significant changes in its senior management personnel. In a recent corporate filing, the company disclosed the resignation of Murari Ranganathan, Commercial Director for Women’s Health, Metabolics, and International Business, and the appointment of Prithwish Kumar Banerji as his successor.

Resignation of Murari Ranganathan

Murari Ranganathan has tendered his resignation from Abbott India, effective close of business hours on February 25, 2025, to pursue opportunities outside the organization. Having served as the Commercial Director, Murari played a pivotal role in driving the company’s growth in critical verticals, including Women’s Health and Metabolics.

The company, in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, has confirmed that the reasons for Murari’s resignation will be shared separately within seven days after his cessation.

Appointment of Prithwish Kumar Banerji

Abbott India has appointed Prithwish Kumar Banerji as the new Commercial Director for Women’s Health, Metabolics, and International Business, effective January 3, 2025. This strategic move underscores Abbott’s commitment to maintaining leadership excellence in its key business areas.

Prithwish Kumar Banerji's Profile
With a career spanning nearly 28 years, Prithwish brings a wealth of experience in sales, marketing, and strategic business planning. He previously held the position of Vice President and Vertical Head for Cipla’s respiratory portfolio, demonstrating his expertise in launching innovative products and implementing successful go-to-market strategies.

Prithwish has also worked with renowned organizations like Unilever, GSK Consumer Healthcare, and Abbott Diabetes Care, where he served as National Sales Manager. His impressive track record includes launching patented pharmaceutical products, creating winning market strategies, and establishing leadership in Pharma, OTC/OTX, and FMCG domains.

Prithwish is an honors graduate in Geology from St. Xavier’s College, Ranchi, and has completed an Executive Management Program from IIM Lucknow.

Strategic Implications for Abbott India

The leadership transition is expected to strengthen Abbott India’s operational efficiency and strategic focus in the competitive pharmaceutical market. The appointment of Prithwish Kumar Banerji aligns with Abbott’s vision to innovate and deliver excellence in its Women’s Health, Metabolics, and International Business divisions.

The Upcoming IPOs in this week and coming weeks are Indobell Insulation, Standard Glass Lining, Quadrant Future, Capital Infra Trust, Delta Autocorp, B R Goyal.

The Current active IPO is   Fabtech Technologies, Leo Dry Fruits, Davin Sons, and Parmeshwar Metal.

For more updates on executive appointments and other business developments, we encourage readers to explore related news and articles, including the latest on IPOs, share market updates, and financial strategies at:
Best IPO to Apply Now - IPO List 2024, Latest IPO, Upcoming IPO, Recent IPO News, Live IPO GMP Today - Finance Saathi
Top News Headlines - Share Market News, Latest IPO News, Business News, Economy News- Finance Saathi.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst & Finance Saathi Telegram Channel for Regular Share Market, News & IPO Updates.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.